CAPTEM
Checked 2026-09-09
Advanced pancreatic neuroendocrine tumour
One cycle
every 28 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Capecitabine | 750 mg/m² twice daily | Oral | D1-14 | |
Temozolomide Oral alkylating chemotherapy | 200 mg/m² | Oral | D10-14 |
Cycles
until progression (E2211 to 13 cycles)
28-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
177Lu-DOTATATE (PRRT)
SSTR-positive gastroenteropancreatic NET after somatostatin analogue
every 56 days × 4
Everolimus
Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy
every 28 days
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4
Sunitinib 4/2
Advanced clear-cell RCC favourable risk or when immunotherapy is contraindicated; imatinib-resistant GIST; pancreatic NET
every 42 days